Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
3.145
+0.085 (2.78%)
Apr 17, 2025, 4:00 PM EDT - Market closed

Arbutus Biopharma Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Net Income
-69.92-72.85-69.46-76.25-63.75
Upgrade
Depreciation & Amortization
1.381.41.431.751.98
Upgrade
Loss (Gain) From Sale of Assets
--0.02---
Upgrade
Asset Writedown & Restructuring Costs
0.17----
Upgrade
Loss (Gain) From Sale of Investments
-3.14-2.2-0.0510.21
Upgrade
Loss (Gain) on Equity Investments
----2.55
Upgrade
Stock-Based Compensation
8.999.37.186.426.16
Upgrade
Other Operating Activities
0.5-3.34-3.7-1.390.98
Upgrade
Change in Accounts Receivable
-0.63-0.42-0.450.41-0.11
Upgrade
Change in Accounts Payable
-2.71-5.765.221.911.67
Upgrade
Change in Unearned Revenue
-1.36-10.6622.46--
Upgrade
Change in Other Net Operating Assets
1.87-1.392.03-1.4-1.13
Upgrade
Operating Cash Flow
-64.85-85.94-35.36-67.53-51.44
Upgrade
Capital Expenditures
-0.18-1.01-0.51-0.81-0.23
Upgrade
Sale of Property, Plant & Equipment
-0.02---
Upgrade
Investment in Securities
23.1351.76-74.43-11.87-14.68
Upgrade
Investing Cash Flow
22.9550.77-74.94-12.68-14.91
Upgrade
Issuance of Common Stock
5230.6531.81137.2486.75
Upgrade
Financing Cash Flow
5230.6531.81137.2486.75
Upgrade
Foreign Exchange Rate Adjustments
-0.050.03-0.020.010.06
Upgrade
Net Cash Flow
10.05-4.49-78.5157.0320.45
Upgrade
Free Cash Flow
-65.03-86.94-35.87-68.34-51.67
Upgrade
Free Cash Flow Margin
-1053.83%-479.27%-91.92%-621.96%-747.32%
Upgrade
Free Cash Flow Per Share
-0.35-0.52-0.24-0.64-0.68
Upgrade
Levered Free Cash Flow
-41.56-51.58-9.73-38.42-30.17
Upgrade
Unlevered Free Cash Flow
-41.47-51.3-8.65-36.63-27.66
Upgrade
Change in Net Working Capital
5.612.22-22.77-0.78-0.22
Upgrade
Updated Mar 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q